ATI-Ⅲ对2型糖尿病雄性KKAy小鼠的治疗效果

The therapeutic effect of ATI-Ⅲon type 2 diabetic male KKAy mice

目的:探讨一种新型肝X-α受体(LXRα)激动剂ATI-Ⅲ[3α,6α,24-三羟基-22-乙二胺-24,24-二(三氟甲基)-5β-胆烷]在雄性KKAy小鼠中的降糖作用。方法:选择8周大的雄性KKAy小鼠,随机分为对照组、10 mg治疗组和20 mg治疗组,每组5只小鼠。比较治疗组和对照组KKAy小鼠治疗前、治疗1周和2周后的血糖浓度、膳食摄入量和体重。利用单因素方差分析和费舍尔最小显著差事后检验的统计学方法分析平均值之间是否存在统计学差异(P<0.05)。结果:治疗2周后,20 mg治疗组[平均血糖浓度(19.15±1.30)mmol·L^-1]与对照组[平均血糖浓度(34.80±1.24)mmol·L^-1]相比,小鼠的血糖水平下降了45%,差异有统计学意义(P<0.05)。10 mg治疗组[平均血糖浓度(26.33±4.23)mmol·L^-1与对照组相比,小鼠的血糖水平降低了24%(P>0.05,差异无统计学意义)。治疗2周后,10 mg治疗组和20 mg治疗组的小鼠平均体重分别为(33.20±0.31)g和(32.21±0.23)g,每天平均摄取食物量分别为(6.01±0.05)g和(6.00±0.28)g;对照组小鼠平均体重为(32.67±0.07)g,每天平均摄取食物量为(6.08±0.26)g,但治疗组和对照组之间的差异均无统计学意义(P>0.05)。结论:ATI-Ⅲ可以激活LXRα从而调节小鼠的血糖代谢,降低雄性KKAy小鼠的血糖水平。ATI-Ⅲ的治疗并不影响小鼠的体重和食物的摄取量。

Objective:To explore the anti-diabetic effect of a novel synthetic liver X receptorα(LXRαselective activator)ATI-Ⅲ[3α,6α,24-trihydroxy-22-ethylenediamine-24,24-bis(trifluoromethyl)-5β-cholane]in male KKAy mice.Methods:Male KKAy mice of 8 weeks old were randomly divided into control group,10 mg group and 20 mg group,with 5 mice in each group.The blood glucose,dietary intake,and body weight of the KKAy mice in the treatment group and the control group were compared before treatment,1 week and 2 weeks after treatment,respectively.Measured values were given as mean±standard error of the mean(SEM).One-way ANOVA and Fisher’s protected least significant difference post hoc test were used as the statistical tools to analyze the significance of difference of the means.Results:After 2-week treatment,compared with the control group[mean blood glucose concentration(34.80±1.24)mmol·L^-1],the blood glucose level in the 20 mg group[mean blood glucose concentration(19.15±1.30)mmol·L^-1]decreased by 45%,and the difference was statistically significant(P<0.05).Compared with the control group,the blood glucose level of the 10 mg group[mean blood glucose concentration(26.33±4.23)mmol·L^-1]decreased by 24%(P>0.05,there was no significantly statistical difference).After 2-week treatment,the average body weight of the mice in the 10 mg group and the 20 mg group were(33.20±0.31)g and(32.21±0.23)g,respectively,while the average daily food intake were(6.01±0.05)g and(6.00±0.28)g,respectively.The average weight of the mice in the control group was(32.67±0.07)g,and the average daily intake of food was(6.08±0.26)g.There was no significant difference between the treatment group and the control group(P>0.05).Conclusion:ATI-Ⅲcan activate LXRαto regulate blood glucose metabolism and reduce blood glucose levels in male KKAy mice.The treatment of ATI-Ⅲdid not affect the weight and food intake of mice.